Literature DB >> 26182389

Iron metabolic disorder in chronic hepatitis C: insights from recent evidence.

Keisuke Hino1, Sohji Nishina2, Yuichi Hara2.   

Abstract

The liver is the major iron storage organ in the body, and therefore iron metabolic disorder is sometimes involved in chronic liver diseases. Chronic hepatitis C is one of the liver diseases that show hepatic iron accumulation. The present review highlights the current concept of hepatic iron overload status in chronic hepatitis C and discusses how iron metabolic disorder develops in this disease, and the impact of hepatic iron overload on disease progression and its relevance to hepatocarcinogenesis. The level of hepatic iron accumulation in chronic hepatitis C should be recognized to be basically mild to moderate and sometimes within the normal range. However, even mild to moderate iron overload in the liver contributes to disease progression and hepatocarcinogenesis in chronic hepatitis C, probably by reinforcing the oxidative stress induced by hepatitis C virus (HCV) protein. The mechanisms by which hepatic iron overload develops in chronic hepatitis C have not been fully elucidated. Reduction of the transcription activity of hepcidin by HCV-induced reactive oxygen species may in part account for it, but the regulation of hepcidin is very complex and may depend on many variables, including the particular stage of the systemic and/or hepatic inflammatory conditions and the circulating transferrin-bound iron and intracellular iron stores. This might explain the variations in hepatic iron concentrations reported among patients with HCV-related chronic liver disease.

Entities:  

Keywords:  Hepatocellular carcinoma; Hepcidin; Phlebotomy

Year:  2012        PMID: 26182389     DOI: 10.1007/s12328-012-0323-4

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  47 in total

1.  Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C.

Authors:  Christopher A Aoki; Lorenzo Rossaro; Rajendra Ramsamooj; David Brandhagen; Mary F Burritt; Christopher L Bowlus
Journal:  J Clin Gastroenterol       Date:  2005-01       Impact factor: 3.062

2.  Up-regulation of transferrin receptor 1 in chronic hepatitis C: Implication in excess hepatic iron accumulation.

Authors:  Hiroyuki Saito; Yoshinori Fujimoto; Takaaki Ohtake; Yasuaki Suzuki; Shinobu Sakurai; Yayoi Hosoki; Katsuya Ikuta; Yoshihiro Torimoto; Yutaka Kohgo
Journal:  Hepatol Res       Date:  2005-04       Impact factor: 4.288

3.  HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis.

Authors:  Andreas Erhardt; Andrea Maschner-Olberg; Claudia Mellenthin; Günther Kappert; Ortwin Adams; Andreas Donner; Reinhard Willers; Claus Niederau; Dieter Häussinger
Journal:  J Hepatol       Date:  2003-03       Impact factor: 25.083

Review 4.  Iron in liver diseases other than hemochromatosis.

Authors:  H L Bonkovsky; B F Banner; R W Lambrecht; R B Rubin
Journal:  Semin Liver Dis       Date:  1996-02       Impact factor: 6.115

Review 5.  Iron in nonhemochromatotic liver disorders.

Authors:  Vamsee Alla; Herbert L Bonkovsky
Journal:  Semin Liver Dis       Date:  2005-11       Impact factor: 6.115

Review 6.  Pathology of hepatic iron overload.

Authors:  Elizabeth M Brunt
Journal:  Semin Liver Dis       Date:  2005-11       Impact factor: 6.115

7.  Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C.

Authors:  Dominique Guyader; Anne-Sophie Thirouard; Lars Erdtmann; Nafissa Rakba; Sylvie Jacquelinet; Hélène Danielou; Michèle Perrin; Anne-Marie Jouanolle; Pierre Brissot; Yves Deugnier
Journal:  J Hepatol       Date:  2006-11-10       Impact factor: 25.083

8.  Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C.

Authors:  Naoki Fujita; Ryosuke Sugimoto; Masaki Takeo; Naohito Urawa; Rumi Mifuji; Hideaki Tanaka; Yoshinao Kobayashi; Motoh Iwasa; Shozo Watanabe; Yukihiko Adachi; Masahiko Kaito
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

9.  Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.

Authors:  Harald Hofer; Christoph Osterreicher; Wolfgang Jessner; Melitta Penz; Petra Steindl-Munda; Friedrich Wrba; Peter Ferenci
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

10.  Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4.

Authors:  Lan Lin; Erika V Valore; Elizabeta Nemeth; Julia B Goodnough; Victoria Gabayan; Tomas Ganz
Journal:  Blood       Date:  2007-05-31       Impact factor: 22.113

View more
  1 in total

1.  Male-specific Association between Iron and Lipid Metabolism Changes and Erythroferrone after Hepatitis C Virus Eradication.

Authors:  Shinjiro Inomata; Daisuke Morihara; Akira Anan; Eri Yamauchi; Ryo Yamauchi; Kazuhide Takata; Takashi Tanaka; Keiji Yokoyama; Yasuaki Takeyama; Makoto Irie; Satoshi Shakado; Tetsuro Sohda; Shotaro Sakisaka; Fumihito Hirai
Journal:  Intern Med       Date:  2021-08-24       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.